Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: A multi-centre cohort study.

Xinning TongChin-Yao ShenHa-Lim JeonYihua LiJu Young ShinShirley Cw ChanKai-Hang YiuNicole L PrattMichael WardChak Sing LauIan Ck WongXue Li Edward Chia-Cheng Lai

Published in: Journal of internal medicine (2023)

There was no difference in the risk of CVE among RA patients initiated with IL-6i, or JAKi compared to TNFi. The finding is consistent in Hong Kong, Taiwan and Korea. This article is protected by copyright. All rights reserved.

Keyphrases

rheumatoid arthritis
end stage renal disease
disease activity
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
systemic lupus erythematosus
patient reported outcomes
patient reported